Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation

被引:32
作者
Patel, P. [1 ,2 ,3 ]
Gupta, P. K. C. [1 ,2 ,3 ]
White, C. M. J. [2 ,4 ]
Stanley, A. G. [4 ]
Williams, B. [5 ,6 ]
Tomaszewski, M. [2 ,3 ,4 ]
机构
[1] Univ Hosp Leicester NHS Trust, Dept Metab Med & Chem Pathol, Leicester, Leics, England
[2] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England
[3] Glenfield Gen Hosp, NIHR Leicester Cardiovasc Biomed Res Unit, Leicester LE3 9QP, Leics, England
[4] Univ Hosp Leicester NHS Trust, Leicester, Leics, England
[5] UCL, Inst Cardiovasc Sci, London, England
[6] Univ Coll London Hosp, Biomed Res Ctr, NIHR, London, England
基金
英国医学研究理事会;
关键词
TREATMENT-RESISTANT HYPERTENSION; SYMPATHETIC DENERVATION; ADHERENCE; URINE; ELIGIBILITY; MEDICATION; TRIAL; DRUGS;
D O I
10.1038/jhh.2015.103
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Renal denervation is a potential therapeutic option for resistant hypertension. A thorough clinical assessment to exclude reversible/spurious causes of resistance to antihypertensive therapy is required prior to this procedure. The extent to which non-adherence to antihypertensive treatment contributes to apparent resistance to antihypertensive therapy in patients considered for renal denervation is not known. Patients (n = 34) referred for renal denervation entered the evaluation pathway that included screening for adherence to antihypertensive treatment by high-performance liquid chromatography-tandem mass spectrometry-based urine analysis. Biochemical non-adherence to antihypertensive treatment was the most common cause of non-eligibility for renal denervation-23.5% of patients were either partially or completely non-adherent to prescribed antihypertensive treatment. About 5.9% of those referred for renal denervation had admitted non-adherence prior to performing the screening test. Suboptimal pharmacological treatment of hypertension and 'white-coat effect' accounted for apparently resistant hypertension in a further 17.7 and 5.9% of patients, respectively. Taken together, these three causes of pseudo-resistant hypertension accounted for 52.9% of patients referred for renal denervation. Only 14.7% of referred patients were ultimately deemed eligible for renal denervation. Without biochemical screening for therapeutic non-adherence, the eligibility rate for renal denervation would have been 38.2%. Non-adherence to antihypertensive treatment and other forms of therapeutic pseudo-resistance are by far the most common reason of 'resistant hypertension' in patients referred for renal denervation. We suggest that inclusion of biochemical screening for non-adherence to antihypertensive treatment may be helpful in evaluation of patients with 'resistant hypertension' prior to consideration of renal denervation.
引用
收藏
页码:368 / 373
页数:6
相关论文
共 50 条
  • [41] Reasons associated with treatment non-adherence in schizophrenia in a Pakistan cohort
    Ahmad, Irshad
    Khalily, Muhammad Tahir
    Hallahan, Brian
    ASIAN JOURNAL OF PSYCHIATRY, 2017, 30 : 39 - 43
  • [42] Non-adherence to treatment in inflammatory bowel disease in Czech Republic
    Cerveny, Petr
    Bortlik, Martin
    Vlcek, Jiri
    Kubena, Ales
    Lukas, Milan
    JOURNAL OF CROHNS & COLITIS, 2007, 1 (02) : 77 - 81
  • [43] Indicators of Non-adherence to Asthma Treatment in Pediatric Primary Care
    Monti, Marcela D.
    Nealis, Rose M.
    JOURNAL OF PEDIATRIC NURSING-NURSING CARE OF CHILDREN & FAMILIES, 2017, 36 : 7 - 12
  • [44] Nurse's Contribution to Alleviate Non-adherence to Hypertension Treatment
    Georgiopoulos, G.
    Kollia, Z.
    Katsi, V.
    Oikonomou, D.
    Tsioufis, C.
    Tousoulis, D.
    CURRENT HYPERTENSION REPORTS, 2018, 20 (08)
  • [45] Factors associated with treatment non-adherence in patients with epilepsy in Brazil
    Maluf Ferrari, Carla Maria
    Cardoso de Sousa, Regina Marcia
    Castro, Luiz H. M.
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2013, 22 (05): : 384 - 389
  • [46] Autonomies in Interaction: Dimensions of Patient Autonomy and Non-adherence to Treatment
    Arrieta Valero, Ion
    FRONTIERS IN PSYCHOLOGY, 2019, 10
  • [47] How to deal with a hypertensive patient who has documented non-adherence to the prescribed antihypertensive therapy?
    Georgianos, Panagiotis I.
    Divani, Maria
    Liakopoulos, Vassilios
    HYPERTENSION RESEARCH, 2024, 47 (10) : 2914 - 2916
  • [48] Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity
    Wulaningsih, W.
    Garmo, H.
    Ahlgren, J.
    Holmberg, L.
    Folkvaljon, Y.
    Wigertz, A.
    Van Hemelrijck, M.
    Lambe, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 172 (01) : 167 - 177
  • [49] The Present and the Future of Cost-Related Non-Adherence in Medicare Part D
    Shrank, William H.
    Polinski, Jennifer M.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2015, 30 (08) : 1045 - 1046
  • [50] Patient Non-adherence and Cancellations Are Higher for Screening Colonoscopy Compared with Surveillance Colonoscopy
    Greenspan, Michael
    Chehl, Navdeep
    Shawron, Krista
    Barnes, Lisa
    Li, Hong
    Avery, Elizabeth
    Sims, Shannon
    Losurdo, John
    Mobarhan, Sohrab
    Melson, Joshua
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (10) : 2930 - 2936